Search
Search
About
Log in
Join
Experiences with
Colon cancer
Posts
Communities
31,742 public posts
Filter results
ESMO 2024: Xaluritamig (AMG 509), a STEAP1 x CD3 XmAb 2+1 immune therapy for Metastatic CRPC: initial results of Phase 1
Xaluritamig, a novel bispecific T-cell engager targeting STEAP1, in patients with metastatic castration-resistant prostate cancer (mCRPC). STEAP1 is a cell surface antigen highly expressed in prostate cancer and is associated with poor prognosis. Xaluritamig is designed to redirect T-cells to kill
Xaluritamig, a novel bispecific T-cell engager targeting STEAP1, in patients with metastatic castration-resistant prostate cancer (mCRPC). STEAP1 is a cell surface antigen highly expressed in prostate cancer and is associated with poor prognosis. Xaluritamig is designed to redirect T-cells to kill
Maxone73
in
Advanced Prostate Cancer
11 days ago
Zytiga and diabetes
I’ve been on the Zytiga/Lupron/Prednisone cocktail for about 13 months now. In that time, my A1C has shot up to where now I have diabetes. Now I know this is a possible side effects of this therapy. My question is, when I’m supposed to come off Zytiga (in about a year) does the A1C drop as well? Any
I’ve been on the Zytiga/Lupron/Prednisone cocktail for about 13 months now. In that time, my A1C has shot up to where now I have diabetes. Now I know this is a possible side effects of this therapy. My question is, when I’m supposed to come off Zytiga (in about a year) does the A1C drop as well? Any
BigJ32
in
Advanced Prostate Cancer
11 days ago
Lupron cost!!!
LEUPROLIDE ACETATE INJECTION (45mg) 6 Month Description/Modifier Billing Code J9217 Provider billed the plan $35,367.50 Total cost (amount the plan approved) $1,896.00 Your share $379.20 🤨 20% HORMONAL CHEMOTHERAPY ADMINISTRATION $0 🤡
LEUPROLIDE ACETATE INJECTION (45mg) 6 Month Description/Modifier Billing Code J9217 Provider billed the plan $35,367.50 Total cost (amount the plan approved) $1,896.00 Your share $379.20 🤨 20% HORMONAL CHEMOTHERAPY ADMINISTRATION $0 🤡
Still_in_shock
in
Advanced Prostate Cancer
11 days ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
ESMO 2024: phase 1/2 trial of oral masofaniten (EPI-7386) plus Enzalutamide compared to Enzalutamide alone in men with mCRPC
This looks promising. The trial enrolled 18 patients who were on androgen deprivation therapy but had not received prior AR pathway inhibitors; some had received chemotherapy in the hormone-sensitive setting. Patients were treated with escalating doses of Masofaniten (EPI-7386), up to 600 mg twice daily
This looks promising. The trial enrolled 18 patients who were on androgen deprivation therapy but had not received prior AR pathway inhibitors; some had received chemotherapy in the hormone-sensitive setting. Patients were treated with escalating doses of Masofaniten (EPI-7386), up to 600 mg twice daily
Maxone73
in
Advanced Prostate Cancer
11 days ago
ESMO 2024: TAMARACK, a randomized phase 2 trial of the B7-H3 targeting ADC Vobramitamab for metastatic CRPC
My sensation is that it is too early to say ho well it works, but SE look pretty harsh! The trial enrolled 181 men with mCRPC who had previously received one androgen receptor pathway inhibitor. Participants were randomized to receive vobramitamab at either 2.0 mg/kg or 2.7 mg/kg every four weeks. The
My sensation is that it is too early to say ho well it works, but SE look pretty harsh! The trial enrolled 181 men with mCRPC who had previously received one androgen receptor pathway inhibitor. Participants were randomized to receive vobramitamab at either 2.0 mg/kg or 2.7 mg/kg every four weeks. The
Maxone73
in
Advanced Prostate Cancer
11 days ago
ESMO 2024 - UpFrontPSMA: randomized study of sequential 177Lu-PSMA-617 and Docetaxel vs Docetaxel in metastatic prostate cancer
Data about overall survival seems immature to me, it seems like there is a slight advantage for the sequential therapy, not very significant, but both arms at 36 months are far away from having reached the median. So I think we have to wait for that parameter. The study enrolled 130 patients with de
Data about overall survival seems immature to me, it seems like there is a slight advantage for the sequential therapy, not very significant, but both arms at 36 months are far away from having reached the median. So I think we have to wait for that parameter. The study enrolled 130 patients with de
Maxone73
in
Advanced Prostate Cancer
11 days ago
ESMO 2024: BMS-986365 in heavily pretreated patients with mCRPC
Ok, I am not so impressed with this new molecule, but here it is. BMS-986365 is designed to inhibit androgen receptor (AR) activity through a dual mechanism of degrading the receptor and blocking its function, aiming to overcome resistance to standard AR pathway inhibitors like enzalutamide and abiraterone
Ok, I am not so impressed with this new molecule, but here it is. BMS-986365 is designed to inhibit androgen receptor (AR) activity through a dual mechanism of degrading the receptor and blocking its function, aiming to overcome resistance to standard AR pathway inhibitors like enzalutamide and abiraterone
Maxone73
in
Advanced Prostate Cancer
11 days ago
177Lu-PNT2002 improves OS compared to ARPIs in metastatic castration resistant prostate cancer
as presented by dr Sartor at ESMO 2024 https://www.urotoday.com/conference-highlights/esmo-2024/esmo-2024-prostate-cancer/154850-esmo-2024-efficacy-of-177lu-pnt2002-in-psma-positive-mcrpc-following-progression-on-an-androgen-receptor-pathway-inhibitor-splash.html
as presented by dr Sartor at ESMO 2024 https://www.urotoday.com/conference-highlights/esmo-2024/esmo-2024-prostate-cancer/154850-esmo-2024-efficacy-of-177lu-pnt2002-in-psma-positive-mcrpc-following-progression-on-an-androgen-receptor-pathway-inhibitor-splash.html
Maxone73
in
Advanced Prostate Cancer
11 days ago
Life after leuprolide
We all know that delaying ADT as long as possible should be a goal and benefit for early detection for men. But with the US healthcare policy in place that is not the case for many of us here on HU as we have a late diagnosis with advanced or metastatic disease that puts on the fast track to BIG pharma
We all know that delaying ADT as long as possible should be a goal and benefit for early detection for men. But with the US healthcare policy in place that is not the case for many of us here on HU as we have a late diagnosis with advanced or metastatic disease that puts on the fast track to BIG pharma
Cyclingrealtor
in
Advanced Prostate Cancer
11 days ago
Urologist Wants to switch from Firmagon & Nubeqa to Lupron with Nubeqa
The urologist started with first injection of Firmagon with Nubeqa and before the end of 28 days wants to switch from Firmagon to Lupron with Nubeqa. I was under impression that Firmagon is better at getting the job done than Lupron? Why switch?
The urologist started with first injection of Firmagon with Nubeqa and before the end of 28 days wants to switch from Firmagon to Lupron with Nubeqa. I was under impression that Firmagon is better at getting the job done than Lupron? Why switch?
Rcole727
in
Advanced Prostate Cancer
11 days ago
Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival, MedPage Today September 15, 2024
While this is mostly relevant for those with bone mets, it does indicate better OS with the combo of Xtandi and Xofigo (2 Xs are better than 1). Several links are available in the article for those who want to dig a bit deeper. ********************************************************************* [
While this is mostly relevant for those with bone mets, it does indicate better OS with the combo of Xtandi and Xofigo (2 Xs are better than 1). Several links are available in the article for those who want to dig a bit deeper. ********************************************************************* [
cujoe
in
Fight Prostate Cancer
11 days ago
Impaired Sensitivity to Thyroid Hormones Associated with Central Obesity in Euthyroid Type 2 Diabetes Mellitus with Overweight & Obesity
A paper of possible interest. But it could be turned round and made YOUR FAULT for having impaired sensitivity. And dislike the language where [i]high levels of TT3RI and TFQIFT3[/i] are referred to as if they are real substances. Not that they are indexes based on measurements. [i]Diabetes Metab
A paper of possible interest. But it could be turned round and made YOUR FAULT for having impaired sensitivity. And dislike the language where [i]high levels of TT3RI and TFQIFT3[/i] are referred to as if they are real substances. Not that they are indexes based on measurements. [i]Diabetes Metab
helvella
Thyroid UK
in
Thyroid UK
12 days ago
luPSMA randomised control trial good early results
https://www.youtube.com/watch?v=S_JvSVlOdZ8 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00440-6/abstract Some phase 2 early results : adding LuPSMA to (ADT + docetaxel) has generated a strong result in men with "newly diagnosed high-volume mHSPC" April 2020 the trial started
https://www.youtube.com/watch?v=S_JvSVlOdZ8 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00440-6/abstract Some phase 2 early results : adding LuPSMA to (ADT + docetaxel) has generated a strong result in men with "newly diagnosed high-volume mHSPC" April 2020 the trial started
street-air
in
Advanced Prostate Cancer
12 days ago
High bilirubin
My husband has been on Abiraterone/prednisone for 10 months and Lupron for 12 months and recently has had an increase in his bilirubin 2.5. His MO has stopped the abiraterone temporarily and has ordered a sonogram of his liver/gallbladder and weekly monitoring of bloodwork. He is also slightly anemic
My husband has been on Abiraterone/prednisone for 10 months and Lupron for 12 months and recently has had an increase in his bilirubin 2.5. His MO has stopped the abiraterone temporarily and has ordered a sonogram of his liver/gallbladder and weekly monitoring of bloodwork. He is also slightly anemic
Averagegilbert
in
Advanced Prostate Cancer
12 days ago
Radium 223 + Enzalutamide increase rPFS in castration resistante prostate cancer
As Tall Allen posted, here is the link to the numbers: https://www.onclive.com/view/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc
As Tall Allen posted, here is the link to the numbers: https://www.onclive.com/view/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc
Maxone73
in
Advanced Prostate Cancer
13 days ago
How did your Docetaxel rechallenge compare to your original chemo treatment?
Mr. Spouse 21 is starting a Docetaxel rechallenge next week--3 rounds then another PMSA-PET scan. If you did a Docetaxel rechallenge as well, can you compare your early experiences with the rechallenge in terms of side effects and effectiveness and where you are now? He developed neuropathy despite using
Mr. Spouse 21 is starting a Docetaxel rechallenge next week--3 rounds then another PMSA-PET scan. If you did a Docetaxel rechallenge as well, can you compare your early experiences with the rechallenge in terms of side effects and effectiveness and where you are now? He developed neuropathy despite using
spouse21
in
Advanced Prostate Cancer
13 days ago
Xofigo+Xtandi beats Xtandi alone for mCRPC
Silke Gillessen presented the early results of PEACE3 at ESMO 2024. Compared to Xtandi alone, Xofigo+Xtandi: • improved radiographic progression-free survival by 31% • improved overall survival by 31% These were men who had predominantly bone metastases and all received a bone strengthening agent
Silke Gillessen presented the early results of PEACE3 at ESMO 2024. Compared to Xtandi alone, Xofigo+Xtandi: • improved radiographic progression-free survival by 31% • improved overall survival by 31% These were men who had predominantly bone metastases and all received a bone strengthening agent
Tall_Allen
in
Advanced Prostate Cancer
13 days ago
Estrogen content for bone health
I had PSA of 250 Gleason 9/10 in 2019 Mar. Was under ADT regime from Jun 19 followed by IMRT in Nov 19. It was 39 sessions of 78 Gy to prostrate, prostrate bed, pelvic nodes. Later in Sep 22 PSA started to rise indicating BCR. In Jan 22 underwent Orchidectomy followed by Nubeqa for 19 months now. I've
I had PSA of 250 Gleason 9/10 in 2019 Mar. Was under ADT regime from Jun 19 followed by IMRT in Nov 19. It was 39 sessions of 78 Gy to prostrate, prostrate bed, pelvic nodes. Later in Sep 22 PSA started to rise indicating BCR. In Jan 22 underwent Orchidectomy followed by Nubeqa for 19 months now. I've
binati
in
Advanced Prostate Cancer
14 days ago
PSA jump from 0.01 to 3.0 6 months after surgery
and path I just got my 2nd PSA result today and it showed my level at 3.0...My prosectomy was done 3/21/24 and surgeon took lymp nodes, floor tissue, margins, etc and path report showed pristine results. I also had PSMA and MRI with contrast pre-surgery and both scans showed no spread and fully contained
and path I just got my 2nd PSA result today and it showed my level at 3.0...My prosectomy was done 3/21/24 and surgeon took lymp nodes, floor tissue, margins, etc and path report showed pristine results. I also had PSMA and MRI with contrast pre-surgery and both scans showed no spread and fully contained
wharr
in
Prostate Cancer Network
14 days ago
PSMA pet scan
Has anyone had a Pylarify (PSMA) pet scan showing no prostate cancer spread but knew that you had some metastasis in at least one lymph node (seen in an older scan and confirmed by biopsy). I know that there are people who are PSMA negative...not sure if my husband is one. He has had a prostatectomy,
Has anyone had a Pylarify (PSMA) pet scan showing no prostate cancer spread but knew that you had some metastasis in at least one lymph node (seen in an older scan and confirmed by biopsy). I know that there are people who are PSMA negative...not sure if my husband is one. He has had a prostatectomy,
mountain6
in
Advanced Prostate Cancer
14 days ago
1
...
7
8
9
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
12557 results
My Ovacome
3585 results
SHARE Metastatic Breast Cancer
2225 results
View top 10 communities
Sort by
Most Relevant
Newest